Cargando…
Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV
For HIV-infected children, formulation development, pharmacokinetic (PK) data, and evaluation of early toxicity are critical for licensing new antiretroviral drugs; direct evidence of efficacy in children may not be needed if acceptable safety and PK parameters are demonstrated in children. However,...
Autores principales: | Ford, Deborah, Turner, Rebecca, Turkova, Anna, Penazzato, Martina, Musiime, Victor, Bwakura-Dangarembizi, Mutsa, Violari, Avy, Chabala, Chishala, Puthanakit, Thanyawee, Sudjaritruk, Tavitiya, Cressey, Tim R., Lallemant, Marc, Gibb, Diana M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071856/ https://www.ncbi.nlm.nih.gov/pubmed/29994919 http://dx.doi.org/10.1097/QAI.0000000000001748 |
Ejemplares similares
-
Adverse bone health among children and adolescents growing up with HIV
por: Sudjaritruk, Tavitiya, et al.
Publicado: (2015) -
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial
por: Bevers, Lisanne A H, et al.
Publicado: (2023) -
Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy
por: Farmer, Ruth E., et al.
Publicado: (2020) -
A Global Research Agenda for Pediatric HIV
por: Penazzato, Martina, et al.
Publicado: (2018) -
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
por: Moore, Cecilia L., et al.
Publicado: (2021)